NEOS Investment Management LLC Sells 8,053 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

NEOS Investment Management LLC trimmed its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 60.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,223 shares of the company’s stock after selling 8,053 shares during the quarter. NEOS Investment Management LLC’s holdings in Janux Therapeutics were worth $280,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in shares of Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after buying an additional 721,563 shares in the last quarter. Vanguard Group Inc. grew its position in Janux Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company’s stock worth $114,379,000 after acquiring an additional 288,402 shares in the last quarter. Point72 Asset Management L.P. grew its position in Janux Therapeutics by 190.2% in the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock worth $17,985,000 after acquiring an additional 259,445 shares in the last quarter. Victory Capital Management Inc. increased its stake in Janux Therapeutics by 715.0% during the fourth quarter. Victory Capital Management Inc. now owns 242,409 shares of the company’s stock worth $12,979,000 after acquiring an additional 212,664 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Janux Therapeutics by 941.8% during the fourth quarter. JPMorgan Chase & Co. now owns 191,603 shares of the company’s stock valued at $10,258,000 after purchasing an additional 173,211 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now owns 82,139 shares in the company, valued at $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the transaction, the director now owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 25,002 shares of company stock worth $1,279,953. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Stock Down 7.2 %

Shares of NASDAQ:JANX opened at $27.00 on Tuesday. The business’s 50 day moving average is $35.33 and its 200 day moving average is $45.87. The stock has a market cap of $1.60 billion, a P/E ratio of -23.08 and a beta of 3.23. Janux Therapeutics, Inc. has a 52-week low of $26.40 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JANX shares. Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. Leerink Partners increased their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Wedbush reaffirmed an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $92.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.